Bicyclerd Limited
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Bicycle Therapeutics Limited (to 2018)
5
Ending by 2030
Feb 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 21, 2026The maintenance fee for Polypeptide Ligands Specific for Plasma Kallikrein (US 10,294,274) comes due Nov 21, 2026. Unpaid by May 21, 2027, it lapses early.
- 1 fee due Dec 13, 2026The maintenance fee for Bicyclic Peptide Ligands Specific for MT1-MMP (US 11,672,868) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 2 fees due Mar 5 to 12, 2027 · next Mar 5
- 1 fee due Apr 15, 2027The maintenance fee for Methods for Treating Cancer (US 10,441,663) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
- 1 fee due May 14, 2027The maintenance fee for PEPTIDE LIGANDS FOR BINDING TO EphA2 (US 11,814,447) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Jul 14, 2027The maintenance fee for Bicyclic Peptide Ligands Specific for MT1-MMP (US 10,532,106) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Modulation of Structured Polypeptide Specificity (US 11,912,794) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 2 fees due Oct 2 to 21, 2027 · next Oct 2
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,644,201 | Structured Peptide Processing In force · High confidence | In force | High confidence | |
| US 9,657,288 | Connector Compound Peptide Phage Display In force · High confidence | In force | High confidence | |
| US 9,670,482 | Multispecific Peptides In force · High confidence | In force | High confidence | |
| US 8,778,844 | Structured Peptide Processing In force · High confidence | In force | High confidence | |
| US 9,518,081 | Peptide Libraries In force · High confidence | In force | High confidence | |
| US 10,800,813 | Modulation of Structured Polypeptide Specificity In force · High confidence | In force | High confidence | |
| US 11,912,794 | Modulation of Structured Polypeptide Specificity In force · High confidence | In force | High confidence | |
| US 9,932,367 | Modification of Polypeptides In force · High confidence | In force | High confidence | |
| US 10,870,679 | Modulation of Structured Polypeptide Specificity In force · High confidence | In force | High confidence | |
| US 11,753,444 | Modulation of Structured Polypeptide Specificity In force · High confidence | In force | High confidence |
Also on record, not counted in the 29: 5 patents in force now held by others · 3 lapsed for an unpaid fee · 1 past the fee grace period. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 16 abandoned